Follow The Filings

SPRY Ars Pharmaceuticals Inc.

Health Care, filed as ARS PHARMACEUTICALS INC (COM), Equity As of 2026 Q2 among managers we track Quote on Google Finance, opens in a new tab

Bought by 1 manager in 2026 Q2, sold by 1

  • 2 Owners
  • Max 0.3%
  • $9.3M
  • 1 add 1 exit

In 2026 Q2 Nathan Fischel added to Ars Pharmaceuticals, while Ron Baron sold out.

Who owns this now

Largest portfolio weights among holders, up to 0.3% (Nathan Fischel, Dafna Capital Management). Not free-float ownership.

  1. Nathan Fischel Add 0.25%
  2. Dan Loeb 0.17%

Who owns SPRY

Sorted by value, long equity only, as of 2026 Q2.

History
Dan Loeb, Third Point 0.17% Hold 1,000,000 $8M History
Nathan Fischel, Dafna Capital Management 0.25% Add +17.9% 164,285 $1.3M History
Ron Baron, Bamco Inc. (Baron Capital) exited 2026 Q2 Last 2026 Q1 0.03% Exit −0.03% 1,273,341 $10M History

2 current, 1 exited last period, options excluded

Weight bar: held both quarters added sold at this quarter’s reported price

Insider trades

Open-market buys and sales by SPRY's executives, directors and 10% owners in the last 12 months, from their Form 4s

All SPRY insider trades
  • None no insider bought on the open market
  • $1.7M sold by 2 insiders outside a trading plan
  • $284K sold by 2 insiders under 10b5-1 plans
  1. Eric Karas Chief Commercial Officer
    Planned sale
    $250K 25,000 shares at $10.00 67% of stake
    Traded Jun 12 Filed Jun 12
    ↗
  2. Alexander A Fitzpatrick Chief Legal Officer
    Planned sale
    $34K 3,355 shares at $10.00 3.6% of stake
    Traded Jun 12 Filed Jun 12
    ↗
  3. Justin Chakma Chief Business Officer
    Sale
    $1.5M 166,380 shares at $8.87 100% of stake
    Traded Nov 12, 2025 Filed Nov 14, 2025
    ↗
  4. Brian Dorsey COO
    Sale
    $190K 21,828 shares at $8.71 67% of stake
    Traded Nov 13, 2025 Filed Nov 14, 2025
    ↗

Also filed in the last 12 months, not counted as buying or selling: 3 option exercises and 2 gifts.

SEC filings

Recent issuer filings from EDGAR, 20 shown.

Filed Form Detail Links
8-K 2.02,9.01 Filing Doc
10-Q Filing Doc
SCHEDULE 13G — Filing Doc
8-K 5.02 Filing Doc
SCHEDULE 13G/A — Filing Doc
8-K 5.02 Filing Doc
8-K 5.07 Filing Doc
SCHEDULE 13G/A — Filing Doc
8-K 2.02,7.01,9.01 Filing Doc
10-Q Filing Doc
8-K 5.02,9.01 Filing Doc
DEF 14A Filing Doc
DEFA14A Filing Doc
SCHEDULE 13G/A — Filing Doc
SCHEDULE 13G/A — Filing Doc
SCHEDULE 13G — Filing Doc
8-K 2.02,7.01,9.01 Filing Doc
10-K Filing Doc
SCHEDULE 13G — Filing Doc
SCHEDULE 13G — Filing Doc

Source: SEC EDGAR submissions, updated 4 days ago. All on EDGAR

Financials

US-GAAP annual figures by fiscal year, as tagged in Form 10-K. Each value links to its SEC filing.

Income statement

Metric FY2023 FY2024 FY2025
Revenue $0.03M $89.15M $84.28M
Net income -$54.36M $8M -$171.3M
Net margin * -181216.7% 9.0% -203.3%

Balance sheet

Metric FY2023 FY2024 FY2025
Total current assets $231.73M $334.3M $284.9M
Total non-current assets * $1.46M $16.86M $42.76M
Total assets $233.19M $351.15M $327.65M
Total current liabilities $2.39M $23.44M $39.14M
Total non-current liabilities * $0.037M $70.92M $174.25M
Total equity $230.76M $256.8M $114.26M

Cash flow

Metric FY2023 FY2024 FY2025
Cash from operations -$59.27M $13.55M -$170.87M
Cash from investing -$87.18M -$106.1M $56.77M
Cash from financing $6.9M $72.4M $104.6M
Net change in cash -$139.55M -$20.15M -$9.5M

Source: SEC companyfacts (US-GAAP 10-K). A * marks a computed figure, not a single XBRL tag. Fiscal years are as the issuer labels them. Follow The Filings does not adjust or audit these figures.

Ownership over time

13Fs that reported it each quarter. Click a bar for that quarter’s holders.